There is currently no vaccine or effective treatment of Ebola and Marburg filoviruses, two deadly viruses that cause hemorrhagic fever, but a new discovery of U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and AVI BioPharma could lead to the first vaccine may protect against viruses that have a 90% mortality in humans.PMO compounds block viral replication in animal studies
Travis K. Warren Research and his colleagues have found two compounds from a family known as antisense phosphorodiamidate morpholio oligomers, or in the PMO. These compounds block critical genetic viral sequences, viral replication to stop long enough to give the immune system time to protect against viruses and remove it from the body.
Nine monkeys exposed to Ebola virus, and eight of them received PMO compound called AVI-6002. The compound is protected 60% of monkeys infected with Ebola virus. In the second experiment, three of the five monkeys in each group survived at a dose of 40 mg of AVI-6002 per kilogram of body weight.
A second compound called PMO AVI-6003 protected 100% of the monkeys infected with Marburg virus Lake Victoria (Merv). Furthermore, it was more than 90% effective in mice and guinea pigs.
Both compounds appeared to protect animals when administered up to one hour after exposure, suggesting they may also be used to treat people who accidentally become infected in laboratories and hospital.
Ebola and Marburg viruses are usually transmitted through blood and body fluids. However, infection can occur through droplets, causing serious concern as a potential weapon in biological warfare or terrorism.
The researchers presented new applications of the study drug (IND) for AVI-6002 and AVI-6003, to U.S. Food and Drug (FDA) and are clinically tested on a small group of volunteers man.
According to the UN World Health Organization (WHO), about 1850 cases of Ebola have occurred since 1976, resulting in approximately 1,200 deaths.
Travis K. Warren Research and his colleagues have found two compounds from a family known as antisense phosphorodiamidate morpholio oligomers, or in the PMO. These compounds block critical genetic viral sequences, viral replication to stop long enough to give the immune system time to protect against viruses and remove it from the body.
Nine monkeys exposed to Ebola virus, and eight of them received PMO compound called AVI-6002. The compound is protected 60% of monkeys infected with Ebola virus. In the second experiment, three of the five monkeys in each group survived at a dose of 40 mg of AVI-6002 per kilogram of body weight.
A second compound called PMO AVI-6003 protected 100% of the monkeys infected with Marburg virus Lake Victoria (Merv). Furthermore, it was more than 90% effective in mice and guinea pigs.
Both compounds appeared to protect animals when administered up to one hour after exposure, suggesting they may also be used to treat people who accidentally become infected in laboratories and hospital.
Ebola and Marburg viruses are usually transmitted through blood and body fluids. However, infection can occur through droplets, causing serious concern as a potential weapon in biological warfare or terrorism.
The researchers presented new applications of the study drug (IND) for AVI-6002 and AVI-6003, to U.S. Food and Drug (FDA) and are clinically tested on a small group of volunteers man.
According to the UN World Health Organization (WHO), about 1850 cases of Ebola have occurred since 1976, resulting in approximately 1,200 deaths.
No comments:
Post a Comment